Kiniksa Pharmaceuticals International (NASDAQ:KNSA) CAO Michael Megna Sells 11,280 Shares of Company Stock

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) CAO Michael Megna sold 11,280 shares of the business’s stock in a transaction that occurred on Monday, November 9th. The shares were sold at an average price of $98.54, for a total value of $1,111,531.20. Following the completion of the sale, the chief accounting officer owned 12,697 shares of the company’s stock, valued at $1,251,162.38. This trade represents a 47.05% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Kiniksa Pharmaceuticals International Price Performance

Shares of NASDAQ:KNSA opened at $96.28 on Friday. Kiniksa Pharmaceuticals International, plc has a 1 year low of $37.02 and a 1 year high of $99.31. The firm has a market capitalization of $7.56 billion, a price-to-earnings ratio of 74.06 and a beta of 0.07. The business’s 50 day moving average price is $81.86 and its 200-day moving average price is $62.44.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last released its quarterly earnings results on Tuesday, October 27th. The company reported $0.56 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.37 by $0.19. The firm had revenue of $285.97 million for the quarter, compared to analysts’ expectations of $260.66 million. Kiniksa Pharmaceuticals International had a net margin of 11.58% and a return on equity of 17.27%. On average, sell-side analysts expect that Kiniksa Pharmaceuticals International, plc will post 1.30 earnings per share for the current year.

Institutional Investors Weigh In On Kiniksa Pharmaceuticals International

Large investors have recently modified their holdings of the business. Bank of America Corp DE raised its position in shares of Kiniksa Pharmaceuticals International by 220.9% in the first quarter. Bank of America Corp DE now owns 735,940 shares of the company’s stock valued at $35,436,000 after buying an additional 506,576 shares during the last quarter. Rubric Capital Management LP lifted its stake in shares of Kiniksa Pharmaceuticals International by 12.7% in the first quarter. Rubric Capital Management LP now owns 3,750,000 shares of the company’s stock worth $180,562,000 after buying an additional 421,347 shares in the last quarter. Janus Henderson Group PLC boosted its position in Kiniksa Pharmaceuticals International by 213.5% during the first quarter. Janus Henderson Group PLC now owns 481,023 shares of the company’s stock worth $23,197,000 after acquiring an additional 327,595 shares during the last quarter. Spruce Street Capital LP boosted its position in Kiniksa Pharmaceuticals International by 75.0% during the first quarter. Spruce Street Capital LP now owns 761,063 shares of the company’s stock worth $36,645,000 after acquiring an additional 326,081 shares during the last quarter. Finally, Pictet Asset Management Holding SA boosted its position in Kiniksa Pharmaceuticals International by 41.3% during the third quarter. Pictet Asset Management Holding SA now owns 860,228 shares of the company’s stock worth $64,182,000 after acquiring an additional 251,578 shares during the last quarter. Hedge funds and other institutional investors own 53.95% of the company’s stock.

Analyst Ratings Changes

A number of analysts have recently commented on the stock. Canaccord Genuity Group boosted their target price on shares of Kiniksa Pharmaceuticals International from $64.00 to $98.00 and gave the stock a “buy” rating in a research note on Wednesday, July 29th. Wells Fargo & Company lifted their price objective on Kiniksa Pharmaceuticals International from $87.00 to $110.00 and gave the stock an “overweight” rating in a report on Wednesday, October 28th. Wedbush boosted their price objective on Kiniksa Pharmaceuticals International from $99.00 to $102.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 28th. Weiss Ratings lowered Kiniksa Pharmaceuticals International from a “buy (b-)” rating to a “hold (c-)” rating in a research note on Wednesday, October 28th. Finally, Zacks Research cut Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “hold” rating in a report on Thursday, July 30th. Seven analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $100.57.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals International plc is a biopharmaceutical company focused on developing and commercializing treatments for patients with autoimmune and inflammatory diseases. The company was established in 2015 and has operations in the United States and internationally. Kiniksa’s marketed medicine, Arcalyst (rilonacept), is approved in the United States to treat recurrent pericarditis and reduce the risk of recurrence in adults and certain pediatric patients. It is also approved for cryopyrin-associated periodic syndromes, a group of rare autoinflammatory conditions.